Navigation Links
WuXi PharmaTech (NYSE: WX) Expands Collaboration With AstraZeneca
Date:6/10/2008

SHANGHAI, China, June 10 /Xinhua-PRNewswire/ -- WuXi PharmaTech (NYSE: WX), a leading pharmaceutical, biotechnology and medical device research and development outsourcing company with operations in China and the United States, announced today that it has signed a new three-year collaboration agreement with AstraZeneca.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO )

In April 2006, WuXi PharmaTech and AstraZeneca entered into a two-year US$14 million collaboration agreement that WuXi PharmaTech successfully delivered more than 100,000 compounds two months ahead of schedule.

"This new collaboration agreement further strengthens our already productive relationship with AstraZeneca, and it is the direct result of our research capability and firm commitment to quality and customer satisfaction," commented Dr. Ge Li, Chairman and Chief Executive Officer of WuXi PharmaTech, "We are hopeful that with our strong and growing drug R&D capabilities the expansion of our collaboration will help AstraZeneca achieve its strategic goals."

Under the new collaboration agreement WuXi PharmaTech will synthesize compounds, according to AstraZeneca's designs, which will further expand AstraZeneca's global compound collection.

"The collaboration with WuXi PharmaTech has exceeded our expectations delivering value to AstraZeneca beyond the cost savings in labor and materials," said Deborah Hartman, Vice President, Lead Generation Discovery Enabling Capabilities and Sciences (DECS), AstraZeneca, "We are looking forward to the prospect of building on this success through our expanded relationship."

High Throughput Screening remains a major source of chemical starting points, making it important to generate many high quality compounds with the proper purity and targeted characteristics. WuXi PharmaTech has developed an innovative, scalable and hi
'/>"/>

SOURCE WuXi PharmaTech
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Quest PharmaTech Announces Positive Results from Phase I Clinical Trial of its Photodynamic Therapy for Actinic Keratosis
2. WuXi PharmaTech Announces First Quarter 2008 Results
3. WuXi PharmaTech (NYSE: WX) Appoints Dr. Peng Wang as VP of Discovery Biology
4. WuXi PharmaTech Schedules First Quarter 2008 Earnings Release on Tuesday, May 27, 2008
5. WuXi PharmaTech (NYSE: WX) Honored Among the BCG 50 Local Dynamos
6. Quest PharmaTech Receives Support from National Research Councils Industrial Research Assistance Program (NRC-IRAP) to develop Ultrasound Technology for the Treatment of Cancer
7. WuXi PharmaTech (Cayman) Inc. Announces Filing of Registration Statement For Follow-On and Secondary Offering
8. WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results
9. WuXi PharmaTech Schedules Fourth Quarter and Full Year 2007 Earnings Release on Wednesday, March 12, 2008
10. WuXi PharmaTech Completes Acquisition of AppTec
11. Quest PharmaTech and BC Cancer Agency to Develop Immuno Photodynamic Therapies for Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... July 10, 2014 Research and Markets ... the "International Photonic Integrated Circuit (Monolithic Integration, ... 2019" report to their offering. ... concept of photonic integration traces its roots in ... promise of photonic integration went unexplored and unfulfilled ...
(Date:7/10/2014)... to the International Atomic Energy Agency (IAEA) the ... acquiring sufficient quantities of plutonium or highly enriched ... device. The IAEA also notes that most cases ... which can be challenging to detect with most ... appearing this week in the Journal of ...
(Date:7/10/2014)... Using microscopic polymer light resonators that expand in ... Quantum Photonics Laboratory have developed new optical sensors ... Optical sensors are ideal for detecting trace gas ... lightweight nature, and immunity to electromagnetic interference. , ... before, the MIT team conceived an extremely sensitive, ...
(Date:7/10/2014)... Understanding the basis of psychiatric disorders has been extremely ... increase risk but are insufficient to cause disease. Now ... Cell Press journal Cell Stem Cell describe ... genetic risks interact with other risk factors or environmental ... Their research pinpoints a genetic variant that may predispose ...
Breaking Biology Technology:International Photonic Integrated Circuit (Monolithic Integration, Hybrid Integration, Module Integration) Market - Forecasts to 2019 2Sensitive detection method may help impede illicit nuclear trafficking 2Swell new sensors 2New strategy could uncover genes at the root of psychiatric illnesses 2
... AMDL, Inc. (Amex:,ADL), with operations in Shenzhen, ... subsidiary Jade Pharmaceutical Inc. (JPI), an international,biopharma ... and,marketing of proprietary pharmaceutical and diagnostic products, ... expansion plans to increase,annualized sales in FY2008, ...
... Nov. 20 Sangamo,BioSciences, Inc. (Nasdaq: SGMO ) ... provide an update on the progress of,Sangamo,s ZFP Therapeutic ... at 11:00 am (ET) on Wednesday, November 28,2007 at ... New York. The presentation will be webcast live ...
... FOLD ) today announced that John F. Crowley, ... at the Lazard Capital,Markets Fourth Annual Healthcare Conference in ... ET at The New York Palace Hotel. A ... available to all,interested parties through the Investors section of ...
Cached Biology Technology:AMDL Launches New JPGreen Business Strategy 2Sangamo BioSciences to Present at the Piper Jaffray Health Care Conference 2Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference 2Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference 3
(Date:7/13/2014)... more effective treatments for cachexia, a profound wasting of ... cancer patients, raising their risk of death, according to ... been tried to reverse the condition, which may cause ... but none have had great success. , Scientists reporting ... Nature , led by Bruce Spiegelman, PhD, demonstrated that ...
(Date:7/11/2014)... The Mills Canyon fire started near the City of ... of local resources, the fire quickly grew to over ... cause of the fire is under investigation by the ... is working with existing local resources in developing fire ... Forest Service (USFS), Washington State Department of Natural Resources, ...
(Date:7/11/2014)... Cell scientists have set a "mouse TRAP" to capture ... a recent study published in the Journal of ... a technique called TRAP to extract cellular and genetic ... by scientists at the Rockefeller Institute for Medical Research ... the protein-making machinery, or ribosomes, of the cell type ...
Breaking Biology News(10 mins):Antibody halts cancer-related wasting condition 2Antibody halts cancer-related wasting condition 3
... at Mount Sinai School of Medicine have discovered a ... and resistance to chemotherapy, and participate in tumor progression. ... tests for early cancer diagnosis, prognostic tests, and innovative ... Resistance to chemotherapy is a frequent ...
... The decision has been taken by the German government to ... The transition process is gaining impetus but much remains to ... wind energy is to be dramatically expanded not only ... still immense potential inland that remains to be tapped, such ...
... appreciate this fabric, which looks innocuous but in fact ... a microcontroller that detects warning signals emitted when the ... can be used to protect buildings, bank vaults, and ... parked overnight at truck stops are particularly vulnerable to ...
Cached Biology News:Researchers reveal a chemo-resistant cancer stem cell as cancer's 'Achilles' heel' 2More accurate wind energy forecasts 2More accurate wind energy forecasts 3A smart fabric sets off the alarm 2A smart fabric sets off the alarm 3
The F40 pump maintenance kit is used to service one F40 pump of a BioLogic DuoFlow workstation. It includes 2 piston seals, 4 check valves, seal removal tool, and 2 O-rings....
... HDAC8 Regulation of gene expression ... as DNA methylation, ATP-dependent chromatin remodeling, ... which include the dynamic acetylation and ... residues present in the tail of ...
...
Mouse monoclonal antibody raised against a partial recombinant PUM2. NCBI Entrez Gene ID = PUM2...
Biology Products: